Dulaglutide

Dulaglutide (Trulicity) is a once-weekly injectable medicine that mimics GLP-1, a gut hormone that controls blood sugar and appetite. Eli Lilly built it as a fusion protein: two copies of a GLP-1 analog are linked to a modified antibody fragment (IgG4 Fc), which protects the drug from fast breakdown and makes one subcutaneous dose per week possible ³.

The FDA approved it in 2014 for glucose control in adults with type 2 diabetes. The label now also covers reducing major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk ⁴. The AWARD phase 3 program established its glucose-lowering effects against placebo, sitagliptin, exenatide twice daily, insulin glargine, and metformin ⁵. The 2019 REWIND trial found a 12% relative reduction in major cardiovascular events, which supported the cardiovascular indication ¹¹.

Registered pens come in 0.75 mg and 1.5 mg strengths, with 3.0 mg and 4.5 mg added in 2020 for people who need additional control ⁷. Beyond diabetes, researchers have tested dulaglutide for excessive thirst (primary polydipsia), multiple sclerosis, and irritable bowel syndrome, though most of that work is small or preclinical ¹⁹.

Dulaglutide works by activating the GLP-1 receptor, the same switch the gut hormone GLP-1 flips after a meal. Activation raises cyclic AMP inside cells and turns on protein kinase A, a signaling cascade confirmed in human heart muscle experiments, where dulaglutide increased contraction force and those effects vanished when the GLP-1 receptor was blocked ².

The metabolic results are the classic incretin effects: insulin release that rises when glucose is high (glucose-dependent), less glucagon, slower stomach emptying, and reduced appetite ¹. Slower gastric emptying is one reason nausea is common, especially in the first weeks.

Its long duration comes from structure, not the receptor. Two GLP-1 analog chains are fused to a modified IgG4 antibody fragment, which the body recycles instead of quickly clearing, so a dose lasts about a week and steady blood levels arrive after 2 to 4 weeks ⁶.

Dulaglutide also appears to reach the brain more readily than some other GLP-1 drugs. A review estimated brain entry at about 62%, the highest among available agents ⁶⁰. In a randomized crossover trial in primary polydipsia, a condition of excessive thirst and drinking, 1.5 mg weekly cut 8-hour fluid intake by 490 mL and 24-hour urine output by 943 mL; a secondary analysis showed suppression of copeptin, a marker of the antidiuretic hormone vasopressin ²¹.

Other explored effects are anti-inflammatory. In lab studies dulaglutide suppresses inflammatory injury in heart muscle cells via the TLR4/NF-kB pathway, and in diabetic mice it reduces liver injury markers tied to ferroptosis, an iron-dependent cell death process ¹⁸. It appears neutral on the stress hormone axis: three weeks of treatment did not change cortisol rhythm or adrenal responses in healthy volunteers ⁵⁸.

Dulaglutide's best-documented effects come from large diabetes trials. In pooled AWARD data, adding 1.5 mg weekly to common oral regimens lowered HbA1c by 1.3-1.6% at six months, with 52-76% of participants below 7% ⁸. AWARD-11 (n=1,842) showed 4.5 mg reduced HbA1c by 1.77% and body weight by 4.6 kg at 36 weeks, versus 1.54% and 3.0 kg on 1.5 mg ⁷.

Cardiovascular outcomes carry the strongest evidence beyond glycemia. REWIND, a trial of 9,901 mostly primary-prevention patients, found a 12% reduction in a composite of heart attack, stroke, and cardiovascular death, with a number needed to treat of 72 ¹¹. Kidney secondary analyses showed slowing of disease progression on measures of albumin in urine, eGFR decline, and a kidney composite ¹⁶.

Weight loss is real but modest. Real-world 52-week data showed -1.14% body weight on dulaglutide versus -6.51% on injectable semaglutide, with 25.0% versus 51.7% achieving at least 5% loss ⁹. An indirect comparison estimated semaglutide 2.0 mg would outperform even dulaglutide 4.5 mg by roughly 2.6 to 3.3 kg ¹⁰.

Emerging effects are less certain:

• Thirst control: a crossover RCT found dulaglutide cut fluid intake by 17% in primary polydipsia ²¹.
• Sexual function: a meta-analysis of 237 men found GLP-1 agonists improved erectile function scores (MD 2.73) and raised total testosterone about 73 ng/dL; dulaglutide shows no erectile dysfunction signal in the FAERS database, unlike semaglutide ²².
• Liver protection: in diabetic mice, 10 weeks of dulaglutide lowered liver enzymes and markers of ferroptosis and fibrosis (animal study) ¹⁸.
• IBS symptoms: a matched observational cohort found slightly fewer coded GI symptoms after starting a GLP-1 agonist ³⁰.
• Multiple sclerosis: a small proof-of-concept trial tested adjunctive dulaglutide; a systematic review found metabolic improvement without change in relapse rate or disability scores ¹⁹.

Published protocols use a fixed-dose subcutaneous regimen, not a weight-based one. Dulaglutide is not dosed per kilogram; identical fixed doses were used across a mean body weight of 95.7 kg in AWARD-11, and efficacy in Chinese patients was similar above and below a BMI of 25 ⁷.

The standard pattern across the AWARD program:

• Initiation: 0.75 mg subcutaneously once weekly for 4 weeks, then reassess ⁵.
• Maintenance: 1.5 mg once weekly is the usual maintenance dose, used across the AWARD program and in REWIND ⁵.
• Escalation for additional control: step to 3.0 mg, then 4.5 mg, at intervals of at least 4 weeks ⁷.
• Add-on use: 1.5 mg weekly added to metformin, sulfonylureas, pioglitazone, SGLT2 inhibitors, or insulin-based regimens ⁸.
• Youth: AWARD-PEDS tested 0.75 mg and 1.5 mg weekly in type 2 diabetes at ages 10 to under 18, with placebo-adjusted 26-week HbA1c reductions of roughly 0.6% and 0.9% ²⁸.

The 4-week minimum step rule is a tolerability compromise: modeling shows escalation at 4-week intervals adds at most 3% new nausea and 1% new vomiting, because GI tolerance builds with time and exposure ⁵⁶. Steady-state levels arrive at 2 to 4 weeks, so changing dose faster undercounts the current dose's effect ⁶.

Timing: once weekly, any time of day, without regard to meals; injection sites are the abdomen, thigh, or upper arm via a single-use prefilled pen ⁶⁶. If a dose is missed, product guidance is to take it when at least 3 days remain before the next scheduled dose, otherwise skip and resume the normal weekly schedule ⁹⁵. For weight loss, expectations should be calibrated: real-world 52-week loss averaged about 4.9 kg (1.14% of body weight), with 25% reaching at least 5% loss, versus 51.7% on injectable semaglutide ⁹.

Approved dulaglutide requires no reconstitution. Trulicity is supplied as a ready-to-use, clear solution in single-dose prefilled pens at 0.75, 1.5, 3.0, and 4.5 mg per 0.5 mL ⁷. The molecule is a fusion protein, two GLP-1 analog chains linked to a modified IgG4 antibody domain, which gives it its week-long action ³.

Handling guidance for the marketed pens:

• Inspect before use; discard any pen with cloudy, discolored, or particulate solution.
• Do not dilute, transfer, or split the single-dose pen contents.
• Unopened pens stay refrigerated at 2-8°C (36-46°F) in the carton, protected from light; do not freeze.
• A pen removed from refrigeration may be kept at room temperature up to 30°C for at most 14 days, then used or discarded ⁹⁵.

Usability studies rate the prefilled auto-injector highly for accuracy and ease of use, which matters for a once-weekly drug ⁶⁶. The protein itself is somewhat delicate: studies of charge variants show aggregates form under stress, so minimize agitation, temperature swings, and light exposure ⁵⁴.

For research-grade lyophilized dulaglutide, standard peptide practice applies: reconstitute with bacteriostatic water or sterile water, roll gently to dissolve, and discard cloudy or particulate solution. The calculator below handles the dilution math for common vial sizes. Compounded GLP-1 products from unapproved bulk substances carry documented impurity and bioequivalence risks, and professional societies discourage them ⁷¹.

Dulaglutide's interaction profile centers on its glucose-dependent insulin action and delayed gastric emptying.

Insulin and sulfonylureas. Dulaglutide itself has low hypoglycemia risk, but risk rises when combined with insulin or secretagogues. AWARD trials used it with titrated insulin glargine and prandial insulin with rare severe hypoglycemia; in one pooled analysis (n=1,784), a single severe case occurred on metformin plus sulfonylurea ⁸. In a real-world canagliflozin combination cohort, practitioners cut sulfonylurea doses in 56% of patients and stopped them in the rest after hypoglycemia ⁷⁸.

SGLT2 inhibitors. Additive glycemic effect (HbA1c about -1.6% at week 16 with canagliflozin) at the cost of additive dehydration risk, since both drug classes reduce fluid intake and GI losses quicken kidney injury ⁷⁸. Euglycemic DKA is reported when dulaglutide is combined with an SGLT2 inhibitor during severe carbohydrate restriction ⁴⁰.

Other drugs of note:

• Warfarin: a dedicated pharmacokinetic study found no dose adjustment needed when coadministered with dulaglutide ⁸¹.
• DPP-4 inhibitors: redundant incretin action, so stopping the DPP-4 inhibitor at dulaglutide initiation is the standard switch pattern ⁶⁷.
• Heart rate drugs: a case of atrial fibrillation exacerbation and evidence of increased contraction force in human atrium prompt caution with beta blockers or digoxin in arrhythmia-prone patients ².
• Calcineurin inhibitors and corticosteroids: coadministration reports exist without a quantifiable interaction; monitoring during titration is sensible ⁸⁸.
• Anesthesia: the 2024 FDA label warning covers pulmonary aspiration during deep sedation from residual stomach contents, so holding dosing about 7 days before elective procedures is the common practice ³⁴.

Alcohol. Rodent studies show long-acting GLP-1 agonists reduce alcohol intake and reward; overlapping nausea is likely ²⁶.

Supplements. Protein intake near 1.2-1.6 g/kg/day plus resistance training addresses the lean-mass loss documented with GLP-1 agonists ³¹. Pediatric data show a 16.9% one-year nutritional-deficiency rate, mostly vitamin D, so micronutrient monitoring accompanies reduced intake ²⁹. A small randomized comparison found a ketogenic diet plus dulaglutide improved glucose and lipids, though extreme carbohydrate restriction with an SGLT2 inhibitor raises euglycemic DKA risk ⁴⁰.

Dulaglutide is studied and approved as continuous weekly therapy. REWIND and SURPASS-CVOT ran uninterrupted dosing for a median of about 4 years, and the cardiovascular benefit depends on sustained exposure, so interrupting treatment is not a studied strategy for cardiorenal protection ¹¹. No randomized trial tests on/off cycling.

What the tolerance evidence actually shows: nausea and vomiting attenuate over weeks at a stable dose, and modeling finds tolerance is time- and concentration-dependent, meaning drug holidays are not needed for GI adaptation ⁵⁶. There is no receptor-level rationale for cycling to restore sensitivity; the GI burden is managed by the 0.75 mg start and slow, 4-week minimum escalation steps ⁷.

Community patterns exist for off-label weight management, typically structured as 12 weeks on followed by 4 to 8 weeks off, repeated two to three times, or a step-down taper after 24 to 52 weeks (community protocols). These are not trial-validated. Real-world interruptions are often forced rather than planned: in one large program, 53% of GLP-1 users experienced at least one medication disruption that functioned as de facto cycling ⁸⁵.

The one evidence-based interruption is peri-procedural. FDA labeling warns of pulmonary aspiration from residual gastric contents during general anesthesia or deep sedation, and practitioners commonly hold one to two weekly doses before elective procedures ³⁴.

Signs that warrant stopping and evaluating rather than cycling: nausea persisting beyond 8-12 weeks, new reflux (a consistent pharmacovigilance signal), severe epigastric pain after a dose increase (pancreatitis risk), an accidental once-daily dosing error, or an allergic-type injection-site reaction ³².

In clinical research, dulaglutide is most often stacked with oral diabetes drugs rather than other peptides. Pooled AWARD data cover 1.5 mg weekly added to metformin, sulfonylureas, metformin plus pioglitazone, and metformin plus SGLT2 inhibitors, producing 1.3-1.6% HbA1c reductions ⁸. A one-year Indian real-world cohort documented dulaglutide plus canagliflozin with about -1.6% HbA1c at week 16 and roughly 4 kg weight loss ⁷⁸.

Insulin combinations are approved study territory: AWARD-2/4/9 used dulaglutide with basal insulin glargine and prandial insulin, with rare severe hypoglycemia when insulin was titrated carefully ⁷⁷.

What not to do: concurrent incretin agonists (semaglutide, liraglutide, tirzepatide, retatrutide) are not studied as simultaneous combinations. The sensible clinical pattern is sequential switching, which SURPASS-SWITCH validated for dulaglutide to tirzepatide ⁴⁷. A Prader-Willi case report describes sequential use of retatrutide, then oral semaglutide, then dulaglutide across a multi-year course achieving very large weight loss ⁸⁶.

For peptide researchers, the most relevant crossover concerns:

• Lean mass: GLP-1 agonists reduce lean body mass and fat-free mass (standardized mean difference -0.52 across 28 studies), so any stack aimed at body recomposition needs protein and resistance training provisioned ³¹.
• Growth hormone secretagogues: tesamorelin, ipamorelin, and CJC-1295/mod GRF have no published coadministration data with dulaglutide; the theoretical interaction is glucose balance, since the two axes push hepatic glucose output in different directions ¹.
• BPC-157: no clinical data with dulaglutide; a plausible overlap is GI tolerability during titration, unproven.

Community stacking practice favors metformin and SGLT2 inhibitors as the pair most consistent with the trial evidence, with sulfonylurea dose reduction built into the plan (practitioner consensus).

Dulaglutide (Trulicity, Eli Lilly) received FDA approval in 2014 for type 2 diabetes, its first global approval ⁴. The label was later expanded to include cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease or multiple risk factors; it is one of three injectable GLP-1 receptor agonists with that indication, alongside semaglutide and liraglutide ¹². The 3.0 mg and 4.5 mg strengths were approved in 2020 ⁵⁰.

It is not approved for obesity. Incretin-class obesity labels belong to liraglutide, semaglutide, tirzepatide, and orforglipron ¹.

Key labeling elements: a boxed warning for thyroid C-cell tumors, with a contraindication for a personal or family history of medullary thyroid carcinoma or MEN2, based on rodent data ⁴⁵. In 2024 the FDA updated labeling to warn of pulmonary aspiration during general anesthesia or deep sedation due to residual gastric contents ³⁴.

International status: EMA authorization since November 2014 ⁹⁵, MHRA authorization and UK launch in 2015 ⁹⁷, TGA registration profiled in Australian Prescriber in 2018 ⁹⁶, authorization in Russia in 2016 ⁶⁷, and public funding approved in New Zealand in 2021 ⁹⁸. Pediatric study data in type 2 diabetes are complete for ages 10 to under 18 ²⁸.

Dulaglutide is not a controlled substance in the US. For sport, GLP-1 receptor agonists are not on the WADA Prohibited List in any category, so no therapeutic use exemption is required under current rules, though the list changes annually (community protocol).

Compounding: professional societies such as the ADA and EASD strongly discourage compounded GLP-1 preparations, citing impurities, bioequivalence gaps, and immunogenicity ⁷¹.

Gastrointestinal effects dominate the profile and are dose-dependent. In AWARD-11 at 36 weeks, nausea ran 13.4% on 1.5 mg, 15.6% on 3.0 mg, and 16.4% on 4.5 mg; vomiting ran 5.6%, 8.3%, and 9.3% ⁷. These effects peak during escalation and attenuate over weeks as tolerance develops, which is why protocols step doses at 4-week minimum intervals ⁵⁶. In SURPASS-CVOT, GI events affected 35.9% of the dulaglutide arm over about four years, and reduced appetite was reported by 78.4% of interviewed participants ⁷².

Injection-site reactions (pain, redness, bruising, itching) make up 33.5% of dulaglutide reports in the FAERS database, mostly mild ³³. Reflux and GERD show elevated reporting in pharmacovigilance, strongest in people 65 and older ³².

Rare but serious reports include:

• Pancreatitis: acute or necrotizing, sometimes shortly after a dose increase, occasionally with normal lipase early ³⁸.
• Liver injury: drug-induced hepatitis with coagulopathy, resolving after stopping ³⁷.
• Kidney injury: acute kidney injury including biopsy-confirmed interstitial nephritis, usually driven by GI fluid losses plus reduced intake ³⁶.
• Euglycemic DKA: reported with concurrent SGLT2 inhibitor use and severe carbohydrate restriction ⁴⁰.
• Anaphylaxis: within an hour of a first dose ⁴².
• Small bowel obstruction requiring resection ⁴¹.
• Autoimmune blistering skin reactions: lichen planus pemphigoides and bullous pemphigoid, single cases ⁷³.
• Tumor marker false positives: reversible, asymptomatic CA19-9 and CA242 elevations that normalize after stopping ⁴⁴.

Hard contraindications: personal or family history of medullary thyroid carcinoma or MEN2, and prior serious hypersensitivity ⁴⁵. Relative cautions include a history of pancreatitis, significant conduction disease or arrhythmia, severe gastroparesis or prior bowel obstruction, and an upcoming procedure with general anesthesia ³⁴.

Windows of uncertainty: whether rare pancreas and liver reports reflect the drug or diabetic baseline risk, the functional meaning of lean-mass loss, and the rare-event profile of the newer 3.0 and 4.5 mg doses ⁷.